Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas

被引：117

作者：

Cortot, Alexis B. ^{[1
,2
]}

Jaenne, Pasi A. ^{[3
]}

机构：

[1] Univ Lille Nord France, Lille Univ Hosp, Hop Calmette, Thorac Oncol Dept, Lille, France

[2] Univ Lille 1, Inst Biol Lille, UMR8161, Siric OncoLille, Lille, France

[3] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA

来源：

EUROPEAN RESPIRATORY REVIEW | 2014年 / 23卷 / 133期

关键词：

D O I：

10.1183/09059180.00004614

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

The discovery of epidermal growth factor receptor (EGFR) mutations in nonsmall cell lung cancer (NSCLC) has allowed the identification of a subset of patients whose tumours are exquisitely sensitive to EGFR tyrosine kinase inhibitors (TKIs). Despite the efficacy and superiority of EGFR TKIs over chemotherapy as first-line therapy, all patients will ultimately develop progressive disease, with a median of 9-13 months progression-free survival. A better understanding of the molecular mechanisms underlying resistance to EGFR TKIs can help design new drugs and therapeutic strategies to overcome resistance. This has been illustrated by the new generation TKIs that are effective on the T790M mutation, which is the most frequent mechanism of acquired resistance to EGFR TKIs. In this article, we will address the main molecular mechanisms of primary and acquired resistance to EGFR TKIs in EGFR-mutant NSCLC.

引用

页码：356 / 366

页数：11

共 88 条

[1] Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines [J].

Alfieri, Roberta R. ;

Galetti, Maricla ;

Tramonti, Stefano ;

Andreoli, Roberta ;

Mozzoni, Paola ;

Cavazzoni, Andrea ;

Bonelli, Mara ;

Fumarola, Claudia ;

La Monica, Silvia ;

Galvani, Elena ;

De Palma, Giuseppe ;

Mutti, Antonio ;

Mor, Marco ;

Tiseo, Marcello ;

Mari, Ettore ;

Ardizzoni, Andrea ;

Petronini, Pier Giorgio .

MOLECULAR CANCER, 2011, 10

[2] EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics [J].

Arcila, Maria E. ;

Nafa, Khedoudja ;

Chaft, Jamie E. ;

Rekhtman, Natasha ;

Lau, Christopher ;

Reva, Boris A. ;

Zakowski, Maureen F. ;

Kris, Mark G. ;

Ladanyi, Marc .

MOLECULAR CANCER THERAPEUTICS, 2013, 12 (02) :220-229

[3] Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay [J].

Arcila, Maria E. ;

Oxnard, Geoffrey R. ;

Nafa, Khedoudja ;

Riely, Gregory J. ;

Solomon, Stephen B. ;

Zakowski, Maureen F. ;

Kris, Mark G. ;

Pao, William ;

Miller, Vincent A. ;

Ladanyi, Marc .

CLINICAL CANCER RESEARCH, 2011, 17 (05) :1169-1180

[4] Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor - Mutant lung adenocarcinomas with acquired resistance to kinase inhibitors [J].

Balak, Marissa N. ;

Gong, Yixuan ;

Riely, Gregory J. ;

Somwar, Romel ;

Li, Allan R. ;

Zakowski, Maureen F. ;

Chiang, Anne ;

Yang, Guangli ;

Ouerfelli, Ouathek ;

Kris, Mark G. ;

Ladanyi, Marc ;

Miller, Vincent A. ;

Pao, William .

CLINICAL CANCER RESEARCH, 2006, 12 (21) :6494-6501

[5] MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib [J].

Bean, James ;

Brennan, Cameron ;

Shih, Jin-Yuan ;

Riely, Gregory ;

Viale, Agnes ;

Wang, Lu ;

Chitale, Dhananjay ;

Motoi, Noriko ;

Szoke, Janos ;

Broderick, Stephen ;

Balak, Marissa ;

Chang, Wen-Cheng ;

Yu, Chong-Jen ;

Gazdar, Adi ;

Pass, Harvey ;

Rusch, Valerie ;

Gerald, William ;

Huang, Shiu-Feng ;

Yang, Pan-Chyr ;

Miller, Vincent ;

Ladany, Marc ;

Yang, Chih-Hsin ;

Pao, William .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (52) :20932-20937

[6] Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network [J].

Beau-Faller, M. ;

Prim, N. ;

Ruppert, A. -M. ;

Nanni-Metellus, I. ;

Lacave, R. ;

Lacroix, L. ;

Escande, F. ;

Lizard, S. ;

Pretet, J. -L ;

Rouquette, I. ;

de Cremoux, P. ;

Solassol, J. ;

de Fraipont, F. ;

Bieche, I. ;

Cayre, A. ;

Favre-Guillevin, E. ;

Tomasini, P. ;

Wislez, M. ;

Besse, B. ;

Legrain, M. ;

Voegeli, A. -C. ;

Baudrin, L. ;

Morin, F. ;

Zalcman, G. ;

Quoix, E. ;

Blons, H. ;

Cadranel, J. .

ANNALS OF ONCOLOGY, 2014, 25 (01) :126-131

[7] Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR [J].

Bell, DW ;

Gore, I ;

Okimoto, RA ;

Godin-Heymann, N ;

Sordella, R ;

Mulloy, R ;

Sharma, SV ;

Brannigan, BW ;

Mohapatra, G ;

Settleman, J ;

Haber, DA .

NATURE GENETICS, 2005, 37 (12) :1315-1316

[8] 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease [J].

Besse, B. ;

Adjei, A. ;

Baas, P. ;

Meldgaard, P. ;

Nicolson, M. ;

Paz-Ares, L. ;

Reck, M. ;

Smit, E. F. ;

Syrigos, K. ;

Stahel, R. ;

Felip, E. ;

Peters, S. .

ANNALS OF ONCOLOGY, 2014, 25 (08) :1475-1484

[9] FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR [J].

Bivona, Trever G. ;

Hieronymus, Haley ;

Parker, Joel ;

Chang, Kenneth ;

Taron, Miquel ;

Rosell, Rafael ;

Moonsamy, Philicia ;

Dahlman, Kimberly ;

Miller, Vincent A. ;

Costa, Carlota ;

Hannon, Gregory ;

Sawyers, Charles L. .

NATURE, 2011, 471 (7339) :523-526

[10] Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors [J].

Blencke, S ;

Ullrich, A ;

Daub, H .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (17) :15435-15440

← 1 2 3 4 5 6 7 8 9 →